clinical trial · NCT00829868
Zaleplon 10 mg Capsules Under Non-Fasting Conditions
Teva Pharmaceuticals USA·phase1·completed·n = 42
HealthyZaleplon 10 mg CapsulesSONATA® 10 mg capsules
brief summary
The objective of this study is to compare the relative bioavailability of zaleplon 10 mg capsules(manufactured and distributed by TEVA Pharmaceuticals USA) with that of SONATA® 10mg capsules (Wyeth-Ayerst Pharmaceuticals) in healthy, non-smoking, adult subjects under non-fasting conditions.
started
Feb 1, 2004
primary completion
Mar 1, 2004
completion
Mar 1, 2004
last updated
Aug 21, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
A Relative Bioavailability Study of Zaleplon 10 mg Capsules Under Non-Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol